Foundational Principles of Acute Upper Gastrointestinal Bleeding
Learning Objective
Describe the foundational principles of acute upper gastrointestinal bleeding (UGIB), including its pathophysiology, clinical presentation, and risk factors relevant to critical care pharmacy practice.
1. Introduction
Acute upper gastrointestinal bleeding (UGIB)—defined as bleeding proximal to the ligament of Treitz—poses a life-threatening challenge, particularly in the intensive care unit (ICU). Pharmacists play a key role in the prevention, early recognition, and multidisciplinary management of UGIB.
Key Aspects:
- Lesson Aims: This chapter reviews the foundational principles of UGIB, emphasizing its relevance to critical care pharmacists who are integral to optimizing patient outcomes.
- Definition and Classification:
- Non-variceal UGIB: Includes peptic ulcers, stress-related mucosal disease (SRMD), and Mallory-Weiss tears.
- Variceal UGIB: Arises from portal hypertension, typically esophageal or gastric varices.
- ICU Impact: UGIB in critically ill patients is associated with increased length of stay, higher transfusion requirements, and an elevated risk of multiorgan failure.
Key Considerations in the ICU
In the ICU, stress-related mucosal disease (SRMD) is a common cause of non-variceal UGIB. Variceal bleeds, though less frequent overall, carry significantly higher mortality and necessitate specific interventions such as vasoactive medications and urgent endoscopy. Early pharmacist involvement is crucial for optimizing prophylactic strategies, ensuring appropriate drug dosing (especially in organ dysfunction), and contributing to interdisciplinary management protocols.
2. Epidemiology and Incidence
UGIB is a significant cause of morbidity, accounting for approximately 500,000 hospitalizations in the United States annually. The incidence and risk factors vary between the general patient population and those in the ICU.
- ICU Incidence: Clinically important UGIB develops in 2–6% of ICU patients. This risk escalates to 15–20% in specific high-risk subgroups, such as patients requiring mechanical ventilation for more than 24 hours or those with coagulopathy.
- General Ward Incidence: In non-critically ill hospitalized patients, UGIB is predominantly due to chronic peptic ulcer disease, with less than 2% developing overt bleeding during their stay.
- Mortality: The mortality rate for general UGIB cases is around 2%. However, in critically ill patients, mortality can be substantially higher, ranging from 10–20%, with variceal bleeds associated with the highest risk of death.
- Trends: There has been an overall decline in UGIB incidence, largely attributed to the eradication of Helicobacter pylori and improved NSAID stewardship. Nevertheless, regional variability persists due to differences in H. pylori prevalence and access to healthcare.
Prophylaxis Considerations
The use of prophylactic agents such as H2-receptor antagonists (H2RAs), sucralfate, and proton pump inhibitors (PPIs) has been shown to reduce the incidence of clinically significant UGIB in at-risk ICU patients. However, their impact on overall mortality remains inconclusive. Furthermore, there is ongoing debate regarding a potential increased risk of hospital-acquired pneumonia with acid-suppressive therapy. Therefore, the decision to initiate prophylaxis requires a careful balance of potential benefits and risks on a case-by-case basis.
3. Pathophysiology of UGIB
UGIB results from either a disruption of the mucosal barrier integrity or the rupture of dilated submucosal veins (varices). In critically ill patients, these primary mechanisms are often exacerbated by systemic derangements.
3.1 Non-variceal Mechanisms
- Acid-Peptic Injury: This occurs due to an imbalance between aggressive factors (gastric acid, pepsin) and protective mucosal defense mechanisms (mucus bicarbonate layer, prostaglandins, adequate blood flow).
- Stress-Related Mucosal Disease (SRMD): Common in ICU patients, SRMD is primarily driven by splanchnic hypoperfusion leading to mucosal ischemia. Reperfusion injury and relative acid hypersecretion can further contribute to mucosal damage.
- Risk Enhancers for Non-Variceal Bleeding:
- Mechanical ventilation (especially >48 hours)
- Hypotension/shock states
- Coagulopathy (e.g., INR >1.5, platelets <50,000/µL)
- Use of NSAIDs or aspirin
- Helicobacter pylori infection (less common as primary ICU cause but can be a factor)
3.2 Variceal Bleeding Mechanisms
- Portal Hypertension: An elevated hepatic venous pressure gradient (HVPG >10-12 mmHg) leads to the formation of portosystemic collaterals, including esophageal and gastric varices.
- Variceal Rupture: These thin-walled varices are prone to rupture when subjected to high intraluminal pressure and wall tension.
- Predictors of Rupture: Endoscopic findings such as large variceal size and the presence of red wale marks (dilated venules on the varix surface) indicate a higher risk of bleeding.
3.3 Systemic Contributors
- Coagulopathy: Common in critical illness, particularly in patients with liver failure (leading to thrombocytopenia and decreased synthesis of clotting factors) or sepsis-induced coagulopathy.
- Anticoagulants/Antiplatelets: Therapeutic use of medications like warfarin, direct oral anticoagulants (DOACs), aspirin, and P2Y12 inhibitors significantly increases bleeding risk.
- Hemodynamic Stress: The use of vasopressors, while necessary for blood pressure support, can exacerbate splanchnic vasoconstriction. Systemic tissue hypoxia can further impair mucosal integrity and repair.
Pharmacologic Adjuncts
In variceal bleeding, vasoconstrictors like octreotide or terlipressin are used to reduce portal pressures and splanchnic blood flow. For peptic ulcer bleeding, adjunctive PPI therapy (typically high-dose intravenous infusion) helps stabilize clots by maintaining a higher intragastric pH, which inhibits pepsin activity and promotes platelet aggregation.
4. Impact of Pre-existing Chronic Diseases
Comorbid conditions significantly modulate the risk of UGIB and influence both prophylactic and management strategies. Critical care pharmacists must consider these factors when evaluating patients.
4.1 Liver Cirrhosis and Portal Hypertension
- Dual Risk: Patients with cirrhosis are at high risk for variceal bleeding due to elevated portal pressures. They also have an increased risk of non-variceal bleeding from portal hypertensive gastropathy and coagulopathy.
- Impaired Synthetic Function: Liver dysfunction leads to reduced synthesis of clotting factors and often thrombocytopenia, further impairing hemostasis.
- Management Considerations: Specific management includes vasoactive drugs (e.g., octreotide) for variceal bleeding, endoscopic band ligation or sclerotherapy, and appropriate use of acid suppression.
4.2 Chronic Kidney Disease (CKD)
- Platelet Dysfunction: Uremic toxins accumulated in CKD impair platelet aggregation and adhesion, contributing to a bleeding diathesis.
- Mucosal Changes: Fluid shifts and uremic effects can cause mucosal edema and increased friability of the gastrointestinal lining.
- Pharmacokinetic Considerations: The efficacy and dosing of medications, such as pantoprazole, may be altered in patients with severe CKD or those on dialysis, requiring close monitoring. Some studies suggest pantoprazole efficacy might be attenuated in dialysis patients.
4.3 Cardiovascular Disease and Antithrombotic Therapy
- Heightened Bleeding Risk: Patients on dual antiplatelet therapy (DAPT, e.g., aspirin plus a P2Y12 inhibitor) or systemic anticoagulants for cardiovascular conditions have a substantially increased risk of UGIB.
- Risk-Benefit Assessment: A critical balance must be struck between managing the acute bleed and mitigating the risk of thrombotic events. Consensus guidelines generally support the early resumption of antithrombotic therapy once hemostasis is adequately secured, but this decision is individualized.
5. Social Determinants of Health (SDoH)
Beyond biomedical variables, social determinants of health play a crucial role in influencing UGIB risk, presentation, and outcomes. Pharmacists should be aware of these factors to provide comprehensive care.
- Medication Access and Adherence:
- Cost barriers can limit access to prescribed prophylactic medications like PPIs or H2RAs.
- Misuse or overuse of over-the-counter (OTC) NSAIDs, often due to lack of awareness or affordability of alternatives, is a common contributor to UGIB.
- Health Literacy:
- Poor understanding of medication instructions or UGIB warning signs (e.g., melena, hematemesis) can delay presentation to healthcare services, leading to more severe bleeding and worse outcomes.
- Socioeconomic Status and Nutrition:
- Malnutrition, often linked to lower socioeconomic status, can impair mucosal healing and immune function, increasing susceptibility to GI injury.
- Lack of access to consistent primary care can result in unmonitored NSAID use and delayed management of conditions like H. pylori infection.
- Mitigation Strategies for Pharmacists:
- Provide clear, patient-centered education on medication use and UGIB symptoms.
- Screen for OTC NSAID use and counsel on appropriate alternatives or gastroprotective strategies.
- Connect patients with medication assistance programs or resources for affordable medications.
- Advocate for interdisciplinary approaches that address SDoH.
Integrating SDoH into Risk Assessment
There is a growing recognition of the need to incorporate social determinants of health into clinical risk assessment tools. Identifying patients at high risk due to adverse social factors can help target interventions, such as enhanced prophylaxis, more intensive education, and closer follow-up, potentially improving outcomes and reducing health disparities in UGIB management.
6. Summary and Clinical Implications
A comprehensive understanding of UGIB epidemiology, pathophysiology, and risk factors is essential for critical care practitioners. Pharmacists play a vital role in risk assessment, prophylactic strategies, and therapeutic management.
Key Takeaways for ICU Practice:
- Risk Assessment: Integrate epidemiological data and pathophysiological understanding into ICU risk assessment tools to identify patients vulnerable to UGIB.
- High-Risk Subgroups: Pay particular attention to patients who are mechanically ventilated, coagulopathic, cirrhotic, have CKD, are on antithrombotic therapy, or face adverse social determinants of health.
- Prophylaxis Considerations: While various agents reduce bleeding risk, the choice requires careful consideration of individual patient factors and potential adverse effects. The table below summarizes some reported relative risk reductions, but head-to-head comparisons in all ICU populations are limited.
| Prophylaxis Agent(s) | Illustrative Relative Risk (RR) for Bleeding | Notes |
|---|---|---|
| Ranitidine + Antacids | 0.13 (in some older studies) | Combination therapy; H2RAs largely replaced by PPIs where indicated. |
| PPIs (e.g., Pantoprazole) | ~0.42 – 0.58 (vs. placebo/no prophylaxis) | Generally considered most effective for SRMD prophylaxis. |
| H2RAs (e.g., Cimetidine, Ranitidine, Famotidine) | Variable, generally less than PPIs | An option, but often less potent acid suppression than PPIs. |
| Sucralfate | Variable, may be comparable to H2RAs | Non-absorbable, coats mucosa; less systemic effects but can interact with other drugs. |
Note: RR values can vary significantly based on patient population, study design, and comparator. This table is for illustrative purposes.
Limitations and Future Directions:
- Risk Scores: Standard UGIB risk scores like Glasgow-Blatchford (GBS) or Rockall have limitations in ICU populations. Emerging machine learning models show promise for improved specificity without sacrificing sensitivity in predicting UGIB in critically ill patients.
- Practice Gaps:
- Optimizing the timing and choice of stress ulcer prophylaxis based on dynamic risk factors.
- Systematically incorporating social determinants of health into risk assessment and care planning.
- Refining and validating ICU-specific UGIB risk scores.
Case Vignette: Application in Practice
A 68-year-old male patient with known liver cirrhosis is admitted to the ICU for septic shock and requires mechanical ventilation. His home medications include warfarin for atrial fibrillation. On day 3 of ICU admission, he develops melena, and his hemoglobin drops from 10 g/dL to 7 g/dL. His BUN:Cr ratio is 35.
Pharmacist’s Interventions & Rationale:
- Recommend IV Pantoprazole Infusion: To provide potent acid suppression, stabilizing potential clots regardless of variceal or non-variceal source, and treating likely SRMD.
- Recommend Octreotide Bolus and Infusion: Given history of cirrhosis, variceal bleeding is high on the differential. Octreotide reduces splanchnic blood flow and portal pressures.
- Hold Warfarin: To mitigate further bleeding in the acute setting. Reversal may be considered based on INR and severity.
- Alert Nutrition Team: For timely initiation of enteral nutrition once hemodynamically stable, which can help maintain gut integrity.
- Communicate with Medical Team: To discuss urgent endoscopy, transfusion goals, and potential need for coagulation factor repletion.
References
- Toews I, Hussain S, et al. Pharmacological interventions for preventing upper GI bleeding in ICU patients: a network meta-analysis. BMJ Evid Based Med. 2024;0(0):1–13.
- Laine L, Barkun AN, et al. ACG Clinical Guideline: Upper GI and Ulcer Bleeding. Am J Gastroenterol. 2021;116(5):899–917.
- Bardou M, Quenot JP, Barkun A. Stress-related mucosal disease in the critically ill. Nat Rev Gastroenterol Hepatol. 2015;12(2):98–107.
- Peery AF, Crockett SD, et al. Burden and cost of GI diseases in the US: Update 2018. Gastroenterology. 2019;156(1):254–272.e11.
- Barbateskovic M, Marker S, et al. Stress ulcer prophylaxis in adult ICU patients: meta-analysis. Intensive Care Med. 2019;45(1):143–158.
- Krag M, Marker S, Perner A, et al. Pantoprazole in patients at risk for GI bleeding in the ICU. N Engl J Med. 2018;379(23):2199–2208.
- Chung CS, Chen CC, et al. Early endoscopy for UGIB in ACS patients: RCT. Sci Rep. 2022;12:5798.
- Lin CC, et al. Risk factors of GI bleeding in clopidogrel users: Nationwide study. Aliment Pharmacol Ther. 2013;38(9):1119–1128.
- Shung DL, Au B, et al. Machine learning model outperforms clinical scores for UGIB. Gastroenterology. 2020;158(1):160–167.
